| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
The surface cell receptor N-formyl peptide receptor (FPR) is bound by N-Formyl-Met-Leu-Phe, which sets off a distinct series of metabolic reactions that result in cellular activation. Under circumstances of osteoblast secretion, the G-coupled peptide receptor N-Formyl-Met-Leu-Phe, or FPR, stimulates osteoblast commitment and suppresses adipogenesis. N-Formyl-Met-Leu-Phe marks the creation of bones and promotes osteogenesis. The expression of peroxisome proliferator-activated receptor-γ1 is inhibited by N-formyl-met-leu-phen. The Ca2+-calmodulin inhibitor II-ERK-CREB signaling pathway combines with FPR1-phospholipase C/phospholipase D to drive the osteochondrogenesis induced by N-Formyl-Met-Leu-Phe [1]. N-Formyl-Met-Leu-Phe is a peptide produced from bacteria that causes human peripheral blood mononuclear cells to express proinflammatory cytokines. By means of signaling, the viral products LPS and N-Formyl-Met-Leu-Phe numerous signals work together to generate responses. TNF-α co-sensing via p65 nuclear translocation is the mechanism that TLR4, IKKβ-IκBα, and NF-κB signaling rely on [2].
|
|---|---|
| ln Vivo |
N-Formyl-Met-Leu-Phe helps zebrafish and rabbits build stronger bones. More than 80% of zebrafish treated with N-formyl-Met-Leu-Phe showed signs of endpoint development at 5 dpf. Runx2 expression rose in response to N-Formyl-Met-Leu-Phe treatment. N-Formyl-Met-Leu-Phe-treated skulls have a large medullary cavity and dense connective tissue, such as periosteum, covering the bone [1]. Calprotectin release from PMN is mediated in vitro by N-Formyl-Met-Leu-Phe. It dose-dependently causes PMNs to release calprotectin. Roughly 10% of total PMN calprotectin is preserved at concentrations of N-Formyl-Met-Leu-Phe ranging from 0.1 to 10.0 nM [3].
|
| References |
|
| Additional Infomation |
N-formyl-L-methionyl-L-leucyl-L-phenylalanine is a tripeptide composed of L-Met, L-Leu and L-Phe in a linear sequence with a formyl group at the amino terminus. It acts as a potent inducer of leucocyte chemotaxis and macrophage activator as well as a ligand for the FPR receptor. It is functionally related to a N-formyl-L-methionine, a L-leucine and a L-phenylalanine. It is a conjugate acid of a N-formyl-L-methionyl-L-leucyl-L-phenylalaninate.
A formylated tripeptide originally isolated from bacterial filtrates that is positively chemotactic to polymorphonuclear leucocytes, and causes them to release lysosomal enzymes and become metabolically activated. |
| Molecular Formula |
C21H31N3O5S
|
|---|---|
| Molecular Weight |
437.5529
|
| Exact Mass |
437.198
|
| CAS # |
59880-97-6
|
| PubChem CID |
443295
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
30
|
| Complexity |
567
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCSC)NC=O
|
| InChi Key |
PRQROPMIIGLWRP-BZSNNMDCSA-N
|
| InChi Code |
InChI=1S/C21H31N3O5S/c1-14(2)11-17(23-19(26)16(22-13-25)9-10-30-3)20(27)24-18(21(28)29)12-15-7-5-4-6-8-15/h4-8,13-14,16-18H,9-12H2,1-3H3,(H,22,25)(H,23,26)(H,24,27)(H,28,29)/t16-,17-,18-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
|
| Synonyms |
Chemotactic peptide fMLF N-Formyl-Met-Leu-Phe, FMLP
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 82.5 mg/mL (~188.55 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2855 mL | 11.4273 mL | 22.8545 mL | |
| 5 mM | 0.4571 mL | 2.2855 mL | 4.5709 mL | |
| 10 mM | 0.2285 mL | 1.1427 mL | 2.2855 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00836368 | COMPLETED | Dietary Supplement: gamma-tocopherol | Allergic Allergy Asthma Asthmatic |
University of North Carolina, Chapel Hill | 2008-12 | Phase 1 |
| NCT04297709 | COMPLETED | Cystic Fibrosis | Mologic Ltd | 2018-02-01 | ||
| NCT01348165 | TERMINATEDWITH RESULTS | Drug: BI 137882 Drug: Placebo |
Healthy | Boehringer Ingelheim | 2011-05 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
